| Drug Name |
Levosimendan |
| Drug ID |
BADD_D01284 |
| Description |
Levosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels. It also relaxes vascular smooth muscle by opening adenosine triphosphate sensitive potassium channels. Levosimendan is used to manage acutely decompensated congestive heart failure. |
| Indications and Usage |
For short term treatment of acutely decompensated severe chronic heart failure (CHF). Also being investigated for use/treatment in heart disease. |
| Marketing Status |
approved; investigational |
| ATC Code |
C01CX08 |
| DrugBank ID |
DB00922
|
| KEGG ID |
D04720
|
| MeSH ID |
D000077464
|
| PubChem ID |
3033825
|
| TTD Drug ID |
D0C4HG
|
| NDC Product Code |
Not Available |
| UNII |
C6T4514L4E
|
| Synonyms |
Simendan | ((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile | Simadax | Dextrosimendan | OR 1259 | OR-1259 | Levosimendan | OR-1855 | OR 1855 |
